Crown Bioscience Opens Singapore Laboratory and Establishes Local Commercial Partner
Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, today announced the opening of a new site in Singapore to expand the company’s capacity to support both global and local biotech and pharma companies engaged in preclinical and translational oncology drug discovery and development.
The new facility will initially offer a broad portfolio of high-demand cell line-derived xenograft (CDX) and syngeneic models, alongside supporting analytical biomarker capabilities including flow cytometry and pathology services. The Company is also collaborating with the established biomedical community in Singapore to bring not only the foundational capabilities of Crown Bioscience’s preclinical services to Singapore but also novel technologies and services.
To support the growth goals for the Singapore site, and with a particular focus on the burgeoning local biotech industry, Crown Bioscience is pleased to announce it has entered into a distribution agreement with Biosys Corporation Pte Ltd., a specialized commercial partner with unique contacts within the Singaporean life sciences ecosystem.
Commenting on the opening of the new laboratory, Keefe Chng, PhD, executive director, and general manager of the Singapore facility, commented; “We are extremely excited to join the local biomedical community. Our core capabilities and experience will help the booming local biotech industry advance their preclinical and translational studies, while at the same time enable Crown Bioscience to bring unique high-end technologies to our global partners.”
Mr Ivan Fu, Director of Biosys Corporation,added: “We believe that Crown Bioscience’s new facility in Singapore will inject a new standard for quality and innovation in the local preclinical market. As a distributor of Crown Bioscience in Singapore, our aim is to accelerate our customers research to improve the future of cancer treatment.”
The investment in Singapore reflects a broader strategy to increase Crown Bioscience’s ability to support APAC-based clients with a local presence. In 2022 the Company announced a joint venture launch with sister company MBL in Japan, alongside facility expansions and upgrades to the Company’s Chinese presence. These investments coincide with the fast-growing biotechnology sector across the region, while recognizing the importance of local understanding and language in support of the company’s client base.
To mark the official site opening, a ribbon cutting event was held in February with executives from Crown Bioscience and Biosys Corporation in attendance.
###
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global CRO that provides preclinical and translational platforms to help our customers advance their R&D in oncology, immuno-oncology, and immune-mediated inflammatory diseases. Crown Bioscience is the exclusive preclinical CRO to offer tumor organoid services with the well-established Hubrecht Organoid Technology. We have developed the largest commercially available PDX collection. We focus on helping our customers develop novel therapies to maximize the chances that patients receive the right treatment at the right time. Founded in 2006, Crown Bioscience has 12 facilities across the United States, Europe, and Asia.
For more information or to get in touch, please visit www.crownbio.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230309005059/en/
Contact information
Media Inquiries:
Crown Bioscience
Louise Stenson
pr@crownbio.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Manhattan Unified Supply Chain Powers Schneider Electric’s Global Distribution and Transportation Transformation7.5.2024 09:00:00 CEST | Press release
Manhattan Associates Inc. (NASDAQ: MANH) today announced that leading global energy management and industrial automation organisation, Schneider Electric has chosen Manhattan Active® Warehouse Management and Manhattan Active® Transportation Management to supercharge its global distribution and transportation network as part of an ongoing business-wide transformation strategy. Manhattan Active® Supply Chain (the combination of Manhattan Active WM and Manhattan Active TM) will be implemented in over 20 distribution centres and Schneider Electric plans to deploy Manhattan Active TM across a further 200+ operational sites. Unifying both warehouse and transportation through Manhattan Active Supply Chain will bring maximum inventory performance, operational efficiency, and workforce agility to the company. Stuart Michael Whiting, senior vice president, GSC Logistics and Planning at Schneider Electric commented: “After 12 successful years with a Manhattan WMS, we decided to update to Manhatta
AYA Bank Goes Live with SmartStream's Digital Payments Platform7.5.2024 09:00:00 CEST | Press release
SmartStream, the financial Transaction Lifecycle Management (TLM®) solutions provider, today announces the successful implementation of its TLM Reconciliations Premium Digital Payments Control solution at AYA Bank, Myanmar’s premier banking institution. This implementation marks a significant advancement for the bank’s digital transformation journey. The industry has seen a recent surge in transaction volumes and AYA Bank recognised the need for an innovative tool capable of efficiently processing the influx of payment transactions. SmartStream’s TLM Reconciliations Premium Digital Payments Control will streamline various tasks including reconciliations, settlement, fee computation, and dispute resolution. Leveraging AI capabilities, the solution will facilitate rapid system adoption and comprehensive management of the bank’s transaction lifecycles. In addition, it will introduce a real-time oversight layer, further enhancing transaction transparency and automating accounting processes
QVC Signs Multi-Year Contract Extensions with SES in Germany and the UK7.5.2024 08:50:00 CEST | Press release
Home shoppers across Germany, Austria and Switzerland as well as the United Kingdom and the Republic of Ireland will continue to receive an immersive, high-quality in-home shopping experience as QVC Germany and QVC UK have extended their partnerships with SES in multi-year agreements. For QVC Germany, the extension secures capacity on SES’s prime neighbourhood at the 19.2 degrees East for QVC HD, QVC2 HD and QVC Style HD channels. For QVC UK, the extension secures capacity over SES’s 28.2/28.5 degrees East satellites for QVC HD, QVC Style HD, QVC Beauty and QVC Extra as well as ground services, including uplinking, encoding and monitoring. QVC is a world leader in video commerce (vCommerce), which includes video-driven shopping across linear TV, ecommerce sites, digital streaming and social platforms. Since the 1990s, QVC has been leveraging SES’s satellites to broadcast their vCommerce channels to audiences in markets around the world. "The long-standing partnership with SES gives us
Galderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in Four Additional Countries7.5.2024 07:00:00 CEST | Press release
Galderma today announced that it has received filing acceptances for nemolizumab for the treatment of patients with prurigo nodularis and for adolescents and adults with moderate-to-severe atopic dermatitis in Australia, Singapore, Switzerland, and the United Kingdom, whose regulatory authorities are members of the Access Consortium. An approval decision is expected from the consortium next year. Nemolizumab is a therapy specifically inhibiting IL-31 signaling to provide safe and rapid relief from the most burdensome symptom of both skin conditions: itch.1-7 The Access Consortium is a collaborative initiative comprised of regulatory authorities which work together to address shared challenges, sharing knowledge and promoting greater collaboration to make regulatory systems more efficient.8 These acceptances are in addition to those received from the U.S. Food and Drug Administration (FDA) and European Medicines Agency for nemolizumab for the treatment of prurigo nodularis and atopic de
IFF Reports First Quarter 2024 Results6.5.2024 23:27:00 CEST | Press release
IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2024. Management Commentary "We have started the year well, with good results across the majority of our business," said IFF CEO Erik Fyrwald. "In the first quarter, we delivered volume growth and productivity gains, which resulted in solid top-and-bottom-line results on a comparable basis. We are off to a good start, yet recognize that it is still early in the year and uncertainty remains. Based on our performance to date and our outlook for the balance of the year, we believe results will likely trend towards the higher-end of our previously announced guidance ranges. We also took important steps in our portfolio optimization strategy by reaching an agreement to sell our Pharma Solutions business and completing the previously announced divestiture of our Cosmetic Ingredients business. These actions, along with the rightsizing of our dividend earlier this year, represent significant steps toward our commi